Cancer Family
Nervous System Neoplasm
CI-CAN-00000038Explore in graph →
Non-malignant1,523 active trials9 approved drugs210 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000038Explore in graph →
Clinical trials
5,873 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04804709 | Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG) | terminated | Phase 1 | 5 | Columbia UniversityOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT05944237 | HTL0039732 in Participants With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 150 | Cancer Research UKOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| Neoantigen Vaccine Therapy Against H3.3-K27M Diffuse Intrinsic Pontine Glioma(ENACTING) |
| completed |
| Phase 1 |
| 16 |
| Yang ZhangOTHER |
| 1 |
| Jun 6, 2025 |
| clinicaltrials |
| NCT03452930 | Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma | completed | Phase 1 | 5 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT02766699 | A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM(CerebralEDV) | completed | Phase 1 | 9 | Engeneic Pty LimitedINDUSTRY | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06541665 | Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL | active not recruiting | Phase 1 | 20 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 3, 2025 | clinicaltrials |
| NCT00527410 | A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis(LMD) | terminated | Phase 1 | 9 | BiogenINDUSTRY | 1 | May 30, 2025 | clinicaltrials |
| NCT02311582 | MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas | completed | Phase 1 / Phase 2 | 55 | Washington University School of MedicineOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT04811196 | A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients | completed | Phase 1 | 56 | University Health Network, TorontoOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT00526812 | A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas | completed | Phase 1 | 54 | BiogenINDUSTRY | 1 | May 28, 2025 | clinicaltrials |
| NCT06902350 | Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors | recruiting | Phase 1 | 102 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | May 25, 2025 | clinicaltrials |
| NCT05187624 | A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma | completed | Phase 1 | 36 | Hoffmann-La RocheINDUSTRY | 5 | May 22, 2025 | clinicaltrials |
| NCT03782415 | Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 64 | MediciNovaINDUSTRY | 1 | May 21, 2025 | clinicaltrials |
| NCT06809517 | Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis | recruiting | Phase 1 / Phase 2 | 34 | Guangzhou Medical UniversityOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT01703507 | Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma | completed | Phase 1 | 17 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT03673787 | A Trial of Ipatasertib in Combination With Atezolizumab(IceCAP) | active not recruiting | Phase 1 / Phase 2 | 87 | Institute of Cancer Research, United KingdomOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT03665545 | Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma(IMA950-106) | completed | Phase 1 / Phase 2 | 18 | University Hospital, GenevaOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT04254419 | Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells | recruiting | Phase 1 | 18 | Nationwide Children's HospitalOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT04342572 | Intra-arterial Chemotherapy for Retinoblastoma(IAC) | completed | Phase 1 | 5 | Washington University School of MedicineOTHER | 1 | May 11, 2025 | clinicaltrials |
| NCT01430351 | Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy | terminated | Phase 1 | 144 | M.D. Anderson Cancer CenterOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT02507583 | Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma | completed | Phase 1 | 33 | david andrewsOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT05289908 | Intrathecal Pemetrexed for Leptomeningeal Metastasis | completed | Phase 1 / Phase 2 | 34 | The First Hospital of Jilin UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT00328458 | EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients | completed | Phase 1 | 39 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT00329589 | A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients | completed | Phase 1 | 54 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT00437372 | Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients | completed | Phase 1 | 39 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT00639262 | Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors | completed | Phase 1 | 35 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT01324635 | Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors | terminated | Phase 1 | 17 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT01550523 | Pilot Immunotherapy Trial for Recurrent Malignant Gliomas | completed | Phase 1 | 13 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT02145910 | Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases | withdrawn | Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 0 | May 2, 2025 | clinicaltrials |
| NCT05664243 | A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 4 | In8bio Inc.INDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT02186509 | Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas | completed | Phase 1 | 17 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06948994 | A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Diagnosed High-risk or Relapsed/Refractory Neuroblastoma | not yet recruiting | Phase 1 / Phase 2 | 15 | Guangzhou Women and Children's Medical CenterOTHER | 0 | Apr 29, 2025 | clinicaltrials |
| NCT05535413 | UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases | recruiting | Phase 1 / Phase 2 | 30 | Hunan Cancer HospitalOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT02026271 | A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma | completed | Phase 1 | 40 | Alaunos TherapeuticsINDUSTRY | 1 | Apr 16, 2025 | clinicaltrials |
| NCT03332667 | MIBG With Dinutuximab +/- Vorinostat | completed | Phase 1 | 45 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT04997317 | Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide(PROMENADE) | recruiting | Phase 1 / Phase 2 | 18 | University Hospital, Basel, SwitzerlandOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT02715609 | Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 35 | Washington University School of MedicineOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06674265 | Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma | recruiting | Phase 1 | 10 | Marzieh EbrahimiINDUSTRY | 1 | Apr 9, 2025 | clinicaltrials |
| NCT03572530 | Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa Ependymoma(5-AZA) | completed | Phase 1 | 3 | The University of Texas Health Science Center, HoustonOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT03690869 | REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma | terminated | Phase 1 / Phase 2 | 57 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 8, 2025 | clinicaltrials |
| NCT05112549 | Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26)(IT-PD1) | recruiting | Phase 1 | 46 | University Hospital TuebingenOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT02420613 | Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma | completed | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT05460507 | Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment | recruiting | Phase 1 | 40 | Plus TherapeuticsINDUSTRY | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06221553 | Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG(CMD03DIPG) | recruiting | Phase 1 | 9 | Chulalongkorn UniversityOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06690216 | Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors(PD-L1-PET) | enrolling by invitation | Phase 1 / Phase 2 | 100 | Man HuOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT01906385 | Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT) | recruiting | Phase 1 / Phase 2 | 55 | Plus TherapeuticsINDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT05034497 | Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases(ReSPECT-LM) | active not recruiting | Phase 1 | 18 | Plus TherapeuticsINDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT02584647 | PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors(PLX3397) | terminated | Phase 1 / Phase 2 | 39 | Gulam ManjiOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT00638898 | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT04239040 | GVAX Plus Checkpoint Blockade in Neuroblastoma | terminated | Phase 1 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 19, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jun 8, 2025source: clinicaltrials